Clinical trials
Idiopathic Pulmonary Arterial Hypertension clinical trials
Below are recruiting idiopathic pulmonary arterial hypertension clinical trials, each written for real people, not researchers. We’re tracking 40 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06388421Recruiting
PH-ILD patient registry: tracking real-world outcomes
This study tracks people with both lung scarring and high blood pressure in the lungs (Group 3 PH-ILD) to better understand the disease and how treatments like Tyvaso work in real life. It may help you and your doctor make more informed decisions about your care.
Birmingham, AlabamaAges 18 years+ - NCT07646860RecruitingPhase 2
Sotatercept for Japanese Children With Pulmonary Arterial Hypertension
This study tests a new medicine called sotatercept in Japanese children who have pulmonary arterial hypertension (PAH)—a condition where blood vessels in the lungs become narrow and stiff, making it harder for the heart to pump blood through them. The medicine may help improve how well their hearts and lungs work together.
Setagaya City, TokyoAges 1–17 - NCT07481981RecruitingPhase 3
Study of once-daily inhaled TPIP for pulmonary arterial hypertension
This trial tests an inhaled medication (TPIP) that opens blood vessels in the lungs to help you breathe easier and be more active. It is for people with PAH who are already on stable treatment and have moderate symptoms.
Santa Barbara, CaliforniaAges 18–75 - NCT07132788Recruiting
How PAH affects muscle mass
This study looks at how pulmonary arterial hypertension (PAH) impacts lean muscle mass. It may help researchers understand changes in your body and find new ways to support your health.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06992440RecruitingPhase 2
Empagliflozin for better right heart function in pulmonary hypertension
This trial tests if a diabetes drug can help people with pulmonary arterial hypertension whose right heart function is reduced. Participants take empagliflozin or a placebo for 24 weeks to see if heart function improves.
Baltimore, MarylandAges 18 years+ - NCT07593027RecruitingPhase 1/Phase 2
Study of IMC-003 for pulmonary arterial hypertension
This trial tests a new drug called IMC-003 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can help improve symptoms and exercise ability when added to your current PAH medications.
Beijing, Beijing MunicipalityAges 18–75 - NCT02966665RecruitingPhase 1
Testing blood vessel function in people of different health conditions
This early study measures how well your blood vessels work using tests that may include MRI. It compares healthy people with people who have conditions like COPD, pulmonary arterial hypertension, heart failure, or high blood pressure, to better understand “vascular function” in health and disease.
Salt Lake City, UtahAges 18 years+ - NCT03169010Recruiting
Study registry for rare lung artery blood pressure problems
This study collects information from people with rare types of pulmonary hypertension (high blood pressure in the lungs) and from healthy volunteers. It helps researchers better understand these conditions, especially using a special lung-heart test to confirm the diagnosis.
Beijing, Beijing MunicipalityAges Any age - NCT04555161Recruiting
Test of an implanted device for pulmonary arterial hypertension
This trial studies an implanted system (the Aria CV Pulmonary Hypertension System) to treat pulmonary arterial hypertension, a serious lung-blood vessel and heart condition. It aims to see whether the device can improve outcomes for people who are still sick despite existing PH medicines.
La Jolla, CaliforniaAges 18 years+ - NCT05462574Recruiting
MRI study of heart fat in pulmonary arterial hypertension
This trial uses MRI (and an additional MRI measurement called MRS) to study fat in the right side of the heart in people with pulmonary arterial hypertension (PAH). It may help researchers understand what’s going on in PAH and how it relates to symptoms and exercise ability.
Nashville, TennesseeAges 18 years+ - NCT05464095Recruiting
Mobile health support for pulmonary arterial hypertension
This study tests whether using a mobile health tool can help people with pulmonary arterial hypertension (PAH) manage their condition in daily life. It’s aimed at adults who are stable on their PAH medicines and can track activity using a wearable device.
Nashville, TennesseeAges 18 years+ - NCT05584722Recruiting
Study risk and resilience in pulmonary arterial hypertension
This study looks at how people with pulmonary arterial hypertension (PAH) and certain genetic risks cope and how their bodies respond over time. It may help researchers understand factors linked to better or worse outcomes, and how different people manage the condition.
Nashville, TennesseeAges 15–80 - NCT05587712RecruitingPhase 2
Sotatercept trial for children with pulmonary arterial hypertension
This Phase 2 trial tests sotatercept, a medicine that targets the blood-vessel changes in pulmonary arterial hypertension (PAH), in children. It may help improve how well the heart and lungs work by changing the underlying disease process.
Los Angeles, CaliforniaAges 1–17 - NCT06104228RecruitingPhase 2
Xenon MRI to detect and track pulmonary hypertension
This trial uses a special MRI scan (using xenon gas) to see how well the lungs are working in people with pulmonary arterial hypertension (PAH). It aims to improve diagnosis and monitoring of PAH from connective tissue disease or unknown cause.
Durham, North CarolinaAges 18–75 - NCT06554301RecruitingPhase 1
Empagliflozin for pulmonary arterial hypertension study
This study tests if the diabetes drug empagliflozin can help people with pulmonary arterial hypertension (PAH), a condition causing high blood pressure in the lungs. It aims to see if the drug improves symptoms and is safe for patients with moderate symptoms.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06658522RecruitingPhase 4
Sotatercept for right heart function in pulmonary hypertension
This study tests a medicine called sotatercept to see if it can improve how the right side of your heart pumps in people with PAH. It may help you feel better and slow down the disease.
Amsterdam, North HollandAges 18–70 - NCT07140484RecruitingPhase 4
Sotatercept for pulmonary arterial hypertension
This study tests a new medication called sotatercept for people with pulmonary arterial hypertension (PAH) who are already on at least two other PAH treatments. The goal is to see if adding sotatercept can improve symptoms and exercise ability.
Edmonton, AlbertaAges 18 years+ - NCT07365332RecruitingPhase 3
IKT-001 for pulmonary arterial hypertension
This study tests a new medicine called IKT-001 for people with pulmonary arterial hypertension (PAH). It aims to see if IKT-001 helps improve exercise ability and other symptoms when added to current PAH therapies.
Louisville, KentuckyAges 18–75 - NCT01347216Recruiting
COMPERA study for lung vessel pressure medicines
This study follows people with different types of high blood pressure in the lungs (pulmonary hypertension) to see how starting specific lung blood vessel medicines affects outcomes. It may help improve how clinicians choose and monitor treatment over time.
LeuvenAges 1 week+ - NCT01884051Recruiting
Study of blood and skin changes in pulmonary hypertension
This study looks at how hormones, metabolism, and body signals relate to pulmonary arterial hypertension. You may be eligible if you (or a family member) have idiopathic, inherited, or related pulmonary arterial hypertension, and you can do required blood and other testing.
Nashville, TennesseeAges Up to 90 years - NCT07604805Recruiting
Chinese herbal medicine for severe lung blood pressure
This trial tests whether Qishen Yiqi Dropping Pills, a traditional Chinese herbal medicine, can safely improve symptoms and heart function in people with severe pulmonary hypertension (abnormally high blood pressure in the lungs). You would take this medicine alongside or instead of other treatments to see if it helps you walk farther and feel better.
Guangzhou, GuagdongAges 18–75 - NCT07558460Enrolling by invitation
Virtual Reality Training for Pulmonary Hypertension Patients
This study tests whether using virtual reality can help people with pulmonary hypertension (a condition affecting blood vessels in the lungs) improve their exercise ability and quality of life. You'll use VR while doing gentle physical activities to see if it's helpful and safe.
Istanbul, FatihAges 18–65 - NCT07284459RecruitingPhase 2
Testing PIPE 791 for idiopathic pulmonary fibrosis
This trial tests an investigational drug called PIPE 791 for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the drug slows lung function decline, and you may continue your current IPF medicine.
Mar del Plata, Buenos AiresAges 40 years+ - NCT06317805RecruitingPhase 4
Three-medicine start vs. two oral pills for new PAH
This study compares starting treatment with three medicines, including a continuous infusion (treprostinil), versus two oral medicines for people newly diagnosed with moderate-to-high risk pulmonary arterial hypertension (PAH). The goal is to see which approach improves heart function and symptoms more effectively.
LinzAges 18–70
Hear when a new Idiopathic Pulmonary Arterial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Idiopathic Pulmonary Arterial Hypertension trials by city
Studies with a site in or near these metro areas.
Idiopathic Pulmonary Arterial Hypertension trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for idiopathic pulmonary arterial hypertension?
- Yes. Clin2 currently lists 40 recruiting idiopathic pulmonary arterial hypertension studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a idiopathic pulmonary arterial hypertension trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a idiopathic pulmonary arterial hypertension trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.